Viemed Healthcare Inc Dossier
|
SectorHealth Care IndustryHealth Care Services Beta (adjusted)1.08 Intrinsic Value $12.34median of 6 methods · middle span $10-$18based on filings through 30 Jun 2026 Market Price $9.10Price as of 30 Sep 2026 UndervaluedIntrinsic value is 36% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $346.6M Enterprise Value $343M Shares Outstanding 40.3M diluted Moat Rating Narrow Next Earnings Date5 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Viemed Healthcare, Inc. (VMD) represents a compelling investment opportunity in the home-based clinical care sector. The company is successfully transitioning from a capital-intensive, ventilator-focused business model to a highly diversified, capital-light platform. Rapid expansion in sleep therapy (PAP) and maternal health is driving robust top-line growth and structurally lower capital intensity, which is translating into record free cash flow generation. Backed by a pristine balance sheet with zero net debt and a newly authorized share repurchase program, Viemed is well-positioned to deliver superior shareholder returns. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$11.00 Mean target$11.00 High · most bullish analyst$11.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $8.5020% Ongoing regulatory pressures and strict compliance criteria for ventilator coverage continue to weigh on the core ventilation segment. Slower-than-expected patient onboarding in sleep therapy and rising clinical labor costs compress Adjusted EBITDA margins below 18%. Base CaseCentral scenario $11.0050% Matches the consensus meanViemed achieves its narrowed 2026 revenue guidance of $312 million to $320 million and Adjusted EBITDA of $65 million to $69 million. Sequential quarterly growth of 3% to 5% is sustained, supported by stable Medicare reimbursement rates and steady execution of the 5% share repurchase program. Bull CaseUpside scenario $15.0030% Accelerated organic growth in sleep therapy and maternal health, combined with successful integration of regional acquisitions, drives revenue to the high end of guidance. Capital intensity falls below 9% of revenue, pushing trailing twelve-month free cash flow past $45 million and triggering multiple expansion. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |